Cargando…

High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting

OBJECTIVE: α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ackermann, Amanda M., Zhang, Jia, Heller, Aryel, Briker, Anna, Kaestner, Klaus H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323890/
https://www.ncbi.nlm.nih.gov/pubmed/28271030
http://dx.doi.org/10.1016/j.molmet.2017.01.003
_version_ 1782510114940387328
author Ackermann, Amanda M.
Zhang, Jia
Heller, Aryel
Briker, Anna
Kaestner, Klaus H.
author_facet Ackermann, Amanda M.
Zhang, Jia
Heller, Aryel
Briker, Anna
Kaestner, Klaus H.
author_sort Ackermann, Amanda M.
collection PubMed
description OBJECTIVE: α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of α-cells. However, tools to target gene ablation or activation specifically of α-cells have been limited, compared to those available for β-cells. Previous Glucagon-Cre and Glucagon-CreER transgenic mouse lines have suffered from transgene silencing, and the only available Glucagon-CreER “knock-in” mouse line results in glucagon haploinsufficiency, which can confound the interpretation of gene deletion analyses. Therefore, we sought to develop a Glucagon-CreER(T2) mouse line that would maintain normal glucagon expression and would be less susceptible to transgene silencing. METHODS: We utilized CRISPR-Cas9 technology to insert an IRES-CreER(T2) sequence into the 3′ UTR of the Glucagon (Gcg) locus in mouse embryonic stem cells (ESCs). Targeted ESC clones were then injected into mouse blastocysts to obtain Gcg-CreER(T2) mice. Recombination efficiency in GCG(+) pancreatic α-cells and glucagon-like peptide 1 positive (GLP1(+)) enteroendocrine L-cells was measured in Gcg-CreER(T2);Rosa26-LSL-YFP mice injected with tamoxifen during fetal development and adulthood. RESULTS: Tamoxifen injection of Gcg-CreER(T2);Rosa26-LSL-YFP mice induced high recombination efficiency of the Rosa26-LSL-YFP locus in perinatal and adult α-cells (88% and 95%, respectively), as well as in first-wave fetal α-cells (36%) and adult enteroendocrine L-cells (33%). Mice homozygous for the Gcg-CreER(T2) allele were phenotypically normal. CONCLUSIONS: We successfully derived a Gcg-CreER(T2) mouse line that expresses CreER(T2) in pancreatic α-cells and enteroendocrine L-cells without disrupting preproglucagon gene expression. These mice will be a useful tool for performing temporally controlled genetic manipulation specifically in these cell types.
format Online
Article
Text
id pubmed-5323890
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53238902017-03-07 High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting Ackermann, Amanda M. Zhang, Jia Heller, Aryel Briker, Anna Kaestner, Klaus H. Mol Metab Original Article OBJECTIVE: α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of α-cells. However, tools to target gene ablation or activation specifically of α-cells have been limited, compared to those available for β-cells. Previous Glucagon-Cre and Glucagon-CreER transgenic mouse lines have suffered from transgene silencing, and the only available Glucagon-CreER “knock-in” mouse line results in glucagon haploinsufficiency, which can confound the interpretation of gene deletion analyses. Therefore, we sought to develop a Glucagon-CreER(T2) mouse line that would maintain normal glucagon expression and would be less susceptible to transgene silencing. METHODS: We utilized CRISPR-Cas9 technology to insert an IRES-CreER(T2) sequence into the 3′ UTR of the Glucagon (Gcg) locus in mouse embryonic stem cells (ESCs). Targeted ESC clones were then injected into mouse blastocysts to obtain Gcg-CreER(T2) mice. Recombination efficiency in GCG(+) pancreatic α-cells and glucagon-like peptide 1 positive (GLP1(+)) enteroendocrine L-cells was measured in Gcg-CreER(T2);Rosa26-LSL-YFP mice injected with tamoxifen during fetal development and adulthood. RESULTS: Tamoxifen injection of Gcg-CreER(T2);Rosa26-LSL-YFP mice induced high recombination efficiency of the Rosa26-LSL-YFP locus in perinatal and adult α-cells (88% and 95%, respectively), as well as in first-wave fetal α-cells (36%) and adult enteroendocrine L-cells (33%). Mice homozygous for the Gcg-CreER(T2) allele were phenotypically normal. CONCLUSIONS: We successfully derived a Gcg-CreER(T2) mouse line that expresses CreER(T2) in pancreatic α-cells and enteroendocrine L-cells without disrupting preproglucagon gene expression. These mice will be a useful tool for performing temporally controlled genetic manipulation specifically in these cell types. Elsevier 2017-01-12 /pmc/articles/PMC5323890/ /pubmed/28271030 http://dx.doi.org/10.1016/j.molmet.2017.01.003 Text en © 2017 Published by Elsevier GmbH. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Ackermann, Amanda M.
Zhang, Jia
Heller, Aryel
Briker, Anna
Kaestner, Klaus H.
High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
title High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
title_full High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
title_fullStr High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
title_full_unstemmed High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
title_short High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
title_sort high-fidelity glucagon-creer mouse line generated by crispr-cas9 assisted gene targeting
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323890/
https://www.ncbi.nlm.nih.gov/pubmed/28271030
http://dx.doi.org/10.1016/j.molmet.2017.01.003
work_keys_str_mv AT ackermannamandam highfidelityglucagoncreermouselinegeneratedbycrisprcas9assistedgenetargeting
AT zhangjia highfidelityglucagoncreermouselinegeneratedbycrisprcas9assistedgenetargeting
AT helleraryel highfidelityglucagoncreermouselinegeneratedbycrisprcas9assistedgenetargeting
AT brikeranna highfidelityglucagoncreermouselinegeneratedbycrisprcas9assistedgenetargeting
AT kaestnerklaush highfidelityglucagoncreermouselinegeneratedbycrisprcas9assistedgenetargeting